Financial Performance - Q1 2025 - Total net revenue for Q1 2025 was $777882 thousand, a decrease compared to $856645 thousand in Q1 2024[6] - Net loss attributable to AdaptHealth Corp was $(7207) thousand in Q1 2025, compared to a net income of $50262 thousand in Q1 2024[6] - Adjusted EBITDA for Q1 2025 was $127938 thousand, with an Adjusted EBITDA Margin of 164%, compared to $158485 thousand and 200% respectively in Q1 2024[6] - Non-Acquired Net Revenue Growth was (21)% in Q1 2025[13] Revenue by Segment - Q1 2025 - Net sales revenue totaled $495522 thousand, representing 637% of total net revenue[11] - Net revenue from fixed monthly equipment reimbursements was $249535 thousand, accounting for 321% of total net revenue[11] - Net revenue from capitated revenue arrangements reached $32825 thousand, which is 42% of total net revenue[12] Debt and Share Information - Q1 2025 - Total long-term debt amounted to $2017434 thousand, with net debt at $1963784 thousand[22] - The Consolidated Total Leverage Ratio was 298[22] - The number of common shares outstanding as of March 31, 2025, was 134941 thousand[23]

Financial Data and Key Metrics Changes - The company reported net revenue of $261 million for Q3, which grew by $21 million sequentially but declined by $25 million year-over-year due to higher fee share from contract renewals [12] - Adjusted EBITDA for Q3 was $73 million, representing a sequential improvement of $21 million and the highest quarterly margin of 28.4% for the fiscal year [12] - GAAP net income from continuing operations increased by $76 million compared to the prior year period, primarily due to asset impairment charges related to Contigo Health in the previous year [12] Business Segment Data and Key Metrics Changes - The Supply Chain Services segment performed above expectations, with gross administrative fees growing driven by higher contract penetration and onboarding of new members [13][15] - Performance Services saw notable sequential revenue and adjusted EBITDA improvement, although consulting revenue was lower compared to the prior year, partially offset by better performance in applied sciences [16] Market Data and Key Metrics Changes - The company experienced broad growth across key categories such as med surg, diagnostics, food, and pharmacy, with gross administrative fees growing 3.5% over the prior year period [14] - The company is actively monitoring tariff impacts and has seen no material disruption across its GPO portfolio, although it remains a fluid situation [6][12] Company Strategy and Development Direction - The company is committed to technology-enabled performance improvement and supply chain excellence, with a focus on AI, machine learning, and automation to drive impact across various healthcare challenges [8][9] - A strategic partnership with Epic was announced, expected to enhance the company's documentation and coding solutions, validating its tech-forward approach [9] Management's Comments on Operating Environment and Future Outlook - Management noted that healthcare providers are under pressure due to rising costs, workforce shortages, and reimbursement challenges, leading to increased demand for the company's services [5][24] - The company is increasing its full-year guidance for adjusted EBITDA and adjusted EPS due to better-than-expected performance in Supply Chain Services [4][19] Other Important Information - The company initiated a $200 million accelerated share repurchase program during the quarter and returned $60 million to shareholders through dividends [17][18] - The company expects to complete the majority of contract renewals by the end of fiscal year 2026, with over 75% of negotiations already completed [47] Q&A Session Summary Question: What is driving the outperformance in both segments? - Management indicated that the outperformance is due to a combination of factors including labor pressures, tariffs, and impending federal changes affecting revenue [24][25] Question: How are customers managing tariff impacts? - Customers are actively working with the company to strategize around tariffs, utilizing data and analytics to make informed purchasing decisions [36][39] Question: What is the significance of pharmaceuticals in revenue? - Pharmaceuticals account for approximately 18.5% of gross administrative fees, with ongoing efforts to expand domestic drug manufacturing [65] Question: What are the expectations for health system customers in Q4? - Management expressed that health systems are under pressure and may not have a significantly positive outlook due to concerns over tariffs and labor markets [70] Question: Are there any one-time items in net admin fee revenue? - There were no one-time items in net administrative fees for the quarter, and the completion of renewals was attributed to effective execution [61][62]

Fiscal 2025 Third-Quarter Earnings Conference Call May 6, 2025 © 2025. ALL RIGHTS RESERVED. | PREMIER INC. | 1 Forward-Looking Statements and Non-GAAP Financial Measures Key Points Forward-looking statements – Statements made in this presentation and the accompanying webcast that are not statements of historical or current facts, such as those related to our ability to advance our business strategies and improve healthcare, our ability to transition to partners or wind down the remaining operations of Conti ...

Group 1 - Sabra Healthcare reported revenue of $183.54 million for the quarter ended March 2025, reflecting a 10.1% increase year-over-year [1] - The company's EPS for the quarter was $0.37, significantly up from $0.11 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $181.82 million, resulting in a surprise of +0.95% [1] Group 2 - The company delivered an EPS surprise of +2.78%, with the consensus EPS estimate being $0.36 [1] - Sabra's shares returned +0.8% over the past month, outperforming the Zacks S&P 500 composite's +0.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3] Group 3 - Interest and other income for the quarter was reported at $10.06 million, exceeding the average estimate of $9.43 million by analysts, representing a +12.5% change year-over-year [4] - Resident fees and services revenue was $77.45 million, slightly below the estimated $77.98 million, but still showing a +17.3% increase compared to the previous year [4] - Rental and related revenues were reported at $96.04 million, compared to the average estimate of $97.02 million, marking a +4.6% year-over-year change [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving HealthEquity, Inc and its officers or directors [1] Financial Performance - On March 18, 2025, HealthEquity reported its financial results for the fourth quarter and fiscal year ending January 31, 2025, with earnings per share that fell short of analyst expectations [3] - The company provided weak guidance for the fiscal year ending January 31, 2026, indicating potential challenges ahead [3] Stock Market Reaction - Following the announcement of disappointing earnings and guidance, HealthEquity's stock price dropped by $17.35 per share, or 17.07%, closing at $84.32 per share on March 19, 2025 [3] Cybersecurity Concerns - HealthEquity's management cited "excess service expense" due to increased cyber threats and fraud attacks, which have been attributed to sophisticated techniques employed by malicious actors [3]

Core Insights - 16 dividend growth companies announced increases in the second half of April, indicating a positive trend in dividend policies among these firms [1] - Predictions are made for an additional 7 companies expected to announce dividend increases in the first half of May, suggesting ongoing confidence in dividend growth [1] Group 1 - The article highlights the effectiveness of investing in dividend growth stocks and reinvesting dividends as a strategy for long-term wealth growth [1] - The author operates a blog, HarvestingDividends.com, which focuses on S&P Dividend Aristocrats and other dividend growth stocks, providing valuable insights for investors [1]

Financial Performance Highlights - Net income attributable to Unitholders for the three months ended March 31, 2025, was $80 million ($0.38 per limited partnership unit), compared to $48 million ($0.23 per limited partnership unit) in the prior period[12, 19] - Adjusted EBITDA for the three months ended March 31, 2025, was $591 million, compared to $544 million in the prior period[12, 19] - Adjusted EFO for the three months ended March 31, 2025, was $345 million ($1.60 per unit), compared to $331 million ($1.53 per unit) in the prior period[19] - Corporate liquidity as of March 31, 2025, was $2,414 million, including $59 million of cash and liquid securities and $2,330 million of availability on credit facilities[19, 24] Segment Performance - Business Services Adjusted EBITDA was $213 million, compared to $205 million in the prior period[13, 45] - Infrastructure Services Adjusted EBITDA was $104 million, compared to $143 million in the prior period, which included contribution from the shuttle tanker operation in offshore oil services that was sold in January 2025[13, 49] - Industrials Adjusted EBITDA was $304 million, compared to $228 million in the prior period, with the advanced energy storage operation contributing $233 million compared to $159 million in the prior period[13, 54] Balance Sheet and Liquidity - Total assets as of March 31, 2025, were $75,887 million, compared to $75,474 million as of December 31, 2024[23] - Non-recourse borrowings in subsidiaries were $42,316 million as of March 31, 2025, compared to $36,720 million as of December 31, 2024[23] - Corporate borrowings were $1,017 million as of March 31, 2025, compared to $2,142 million as of December 31, 2024[23] Capital Structure - Partnership units outstanding were 141.0 million as of March 31, 2025, compared to 144.0 million as of December 31, 2024[30] - BBUC exchangeable shares outstanding were 71.7 million as of March 31, 2025, compared to 73.0 million as of December 31, 2024[30] - The company invested approximately $140 million to repurchase 5.9 million of its units and shares at an average price of approximately $24 per unit and share during the quarter and subsequent to quarter end[22]

Core Viewpoint - Select Medical Holdings Corporation reported a 2.4% increase in revenue for Q1 2025, alongside a significant rise in net income from continuing operations, indicating a positive financial trajectory despite challenges in certain segments [2][12]. Financial Performance - Revenue for Q1 2025 reached $1,353.2 million, up from $1,321.2 million in Q1 2024 [2]. - Income from continuing operations before other income and expense was $112.7 million, a decrease from $118.5 million year-over-year [2]. - Net income from continuing operations increased by 21.5% to $74.7 million compared to $61.5 million in the prior year [2]. - Adjusted EBITDA for Q1 2025 was $151.4 million, down from $165.8 million in Q1 2024 [2]. - Earnings per share from continuing operations rose by 33.3% to $0.44, compared to $0.33 in the same quarter last year [2]. Segment Performance - **Critical Illness Recovery Hospital Segment**: Revenue decreased by 2.9% to $637.0 million, with Adjusted EBITDA down 25.3% to $86.6 million [5][23]. - **Rehabilitation Hospital Segment**: Revenue increased by 15.7% to $307.4 million, with Adjusted EBITDA rising by 14.7% to $70.4 million [6][23]. - **Outpatient Rehabilitation Segment**: Revenue increased by 1.4% to $307.3 million, while Adjusted EBITDA slightly decreased to $24.3 million [7][24]. Company Overview - Select Medical operates 104 critical illness recovery hospitals, 35 rehabilitation hospitals, and 1,911 outpatient rehabilitation clinics across 40 states and the District of Columbia as of March 31, 2025 [4]. Dividend and Stock Repurchase - The Board of Directors declared a cash dividend of $0.0625 per share, payable on or about May 29, 2025 [8]. - A stock repurchase program was authorized for up to $1.0 billion, with 649,804 shares repurchased at a cost of approximately $11.4 million during Q1 2025 [10][11]. Business Outlook - For fiscal year 2025, Select Medical expects revenue between $5.3 billion and $5.5 billion, Adjusted EBITDA between $510 million and $530 million, and fully diluted earnings per share between $1.09 and $1.19 [12].

Centene (CNC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a ch ...

Core Insights - Wall Street analysts anticipate IQVIA Holdings (IQV) to report quarterly earnings of $2.63 per share, reflecting a year-over-year increase of 3.5% [1] - Expected revenues for the quarter are projected at $3.77 billion, which represents a 0.9% increase from the previous year [1] Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 0.1%, indicating a collective reassessment by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions to the stock, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock price performance [3] Revenue Projections - Analysts estimate 'Revenues- Technology & Analytics Solutions' to be $1.52 billion, indicating a year-over-year increase of 4.4% [5] - The consensus for 'Revenues- Research & Development Solution' is projected at $2.08 billion, suggesting a decline of 0.9% year over year [5] - 'Revenues- Contract Sales & Medical Solutions' is expected to reach $183.42 million, reflecting a year-over-year decrease of 3% [5] Segment Profit Estimates - The estimated 'Backlog' for IQVIA is $31.43 billion, up from $30.1 billion in the same quarter last year [6] - Analysts project 'Segment Profit- Technology & Analytics Solution' to be $365.56 million, an increase from $335 million reported in the same quarter last year [6] - 'Segment Profit- Contract Sales & Medical Solutions' is expected to be $15.65 million, compared to $13 million in the same quarter last year [7] - The average prediction for 'Segment Profit- Research & Development Solutions' is $471.69 million, slightly down from $479 million reported in the same quarter last year [7] Stock Performance - IQVIA shares have decreased by 11.1% over the past month, contrasting with a decline of 0.7% in the Zacks S&P 500 composite [7] - With a Zacks Rank of 4 (Sell), IQV is expected to underperform the overall market in the near term [7]